BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases
Key Highlights
- ➤BioVie invited to deliver two oral bezisterim presentations at AD/PD2027.
- ➤57-patient SUNRISE-PD trial found strongest responses among patients with higher baseline platelet counts.
- ➤Bezisterim improved MDS-UPDRS non-motor scores versus placebo in the prespecified subgroup.
- ➤Bezisterim improved MDS-UPDRS motor scores versus placebo in the prespecified subgroup.
- ➤CBS clinically meaningful improvement occurred in 25% with bezisterim versus 4% with placebo.
Expert Statements
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“These results provide evidence that an anti-inflammatory treatment can benefit both motor and, importantly, non-motor symptoms of Parkinson’s disease.”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“Because non-motor symptoms remain a significant unmet need, the breadth of activity observed with bezisterim is particularly encouraging for its development as a treatment for early Parkinson’s disease.”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“In SUNRISE-PD we observed a consistent pattern of improvement across motor symptoms, non-motor symptoms, and daily functioning, with particularly encouraging results among patients with higher baseline platelet counts, a potential marker of systemic inflammation.”
Clarence Ahlem, Senior Vice President and Program Lead for Parkinson’s Disease at BioVie
“We believe these findings provide an important foundation for future studies and support the development of bezisterim as a treatment with the potential not only to provide symptomatic benefit, but also to impact the underlying disease process and potentially slow disease progression.”
CARSON CITY, Nev., Nov. 10, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present two oral presentations at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases to be held in Barcelona, Spain from March 16-20, 2027.
The two presentations will be shared during the “AD, PD and Lewy Body Disorders: Novel Therapies” session being held on Saturday, March 20.
Get started
Create a free account to read the full story.